Transparency notifications BlackRock, Inc. |
Brussels (Belgium), 6 July 2018 – 20:00 (CEST) – regulated information 1. Summary of the notifications Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications both dated 3 July 2018 from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.). In the first notification BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights and equivalent financial instruments by its affiliates, its shareholding in UCB SA has increased and has crossed the 5% threshold on 29 June 2018. In the second notification, BlackRock, Inc. has informed that, following a disposal of UCB shares with voting rights and equivalent financial instruments by its affiliates, its shareholding in UCB SA/NV has decreased and has crossed downward the 5% threshold on 2 July 2018. On 29 June 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 000 969 UCB shares with voting rights (versus 5 836 096 shares in its previous notification dated 2 June 2017), representing 4.63% of the total number of shares issued by the company (194 505 658) (versus 3.00% in the notification dated 2 June 2017), as well as 790 335 equivalent financial instruments (versus 379 722 in its previous notification dated 2 June 2017) representing 0.41% of the total number of shares issued by the company (versus 0.20% in the notification dated 2 June 2017). On 2 July 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 8 780 237 UCB shares with voting rights, representing 4.51% of the total number of shares issued by the company, as well as 779 207 equivalent financial instruments, representing 0.40% of the total number of shares issued by the company. 2. Content of the notifications 2.1 The information mentioned hereafter was identical in both notifications:
Please see the full chain of control in the PDF which is attached to the notifications. 2.2. The first transparency notification dated 3 July 2018 included the following specific information: • Date on which the threshold is crossed: 29 June 2018 • Notified details: • Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 5%. 2.3. The second transparency notification dated 3 July 2018 includes the following specific information: • Date on which the threshold is crossed: 2 July 2018 • Notified details: • Additional information: The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going below 5%. 3. Further information This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link. An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link. Investor Relations Antje Witte, Investor Relations, UCB Isabelle Ghellynck, Investor Relations, UCB T +32 2 559 94 14, antje.witte@ucb.com T +32 2 559 95 88, isabelle.ghellynck@ucb.com About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news Open PDF of "Transparency Notification July 6, 2018 ENG" Open PDF of "Transparency Notification July 6, 2018 FR" Open PDF of "Transparency Notification July 6, 2018 NL" |